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Chlamydial infection is the most common sexually transmitted infection (STI), and is caused by the
bacterium Chlamydia trachomatis; however, its overall prevalence rate is not available because it is not a
notiﬁable disease, i.e., it is not reported by government authorities. Therefore, based on the reports of the
limited studies available, the prevalence rate of chlamydial infection among patients visiting STI and
genitourinary clinics was found to be approximately 16e18%. The risk factors for chlamydial infection are
younger age (age 30 years), inconsistent condom use, being symptomatic (dysuria or urethral
discharge) at the time of testing, and having Neisseria gonorrhoeae infection. In Taiwan, the most
commonly reported strain of Chlamydia is genotype E, which is followed by genotypes D and Da, F, K, J, G,
and H. C. trachomatis infection is detected using nucleic acid ampliﬁcation test (NAAT), cell culture, direct
immunoﬂuorescence, enzyme immunoassay, and nucleic acid hybridization test. Among these tests,
NAAT is the most sensitive Food and Drug Administration-approved urine test for diagnosing the
C. trachomatis infection. The primary treatment for chlamydial infection includes either the adminis-
tration of azithromycin (single dose of 1 g orally) or doxycycline (100 mg twice daily for 7 days); both
being equally effective. Chlamydia-infected women and men should be retested approximately 3 months
after the initial treatment. For pregnant women, however, the test should be repeated 3 weeks after the
completion of therapy to ensure therapeutic cure.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Chlamydial infection is the most common sexually transmitted
infection (STI) caused by the bacterium Chlamydia trachomatis and
has a high prevalence rate of untreated asymptomatic patients. In
addition, it was proven to be correlated with the incidence of pelvic
inﬂammatory disease (PID). The incidence rate of chlamydial
infection has been on the rise since 1995 and now it is the most
common bacterial STI.1,2 Previously, urethritis caused by Neisseria
gonorrhoeae was the most common STI, with reports suggesting
gradual decline in its prevalence rate in developed countries. In
Taiwan, however, in addition to gonorrhea, the incidence and
prevalence of chlamydial infection are also on the rise. From a
microbiological perspective, C. trachomatis is a Gram-negative
obligated intracellular bacteria with several virulent serotypes (D,
E, F, G, H, I, J, and K).3 Its incubation period ranges from 3 to 14
days.1 Based on previously published data on C. trachomatis infec-
tion, the trend, epidemiology, risk, treatment, and follow-up will be
reviewed in this article.ina Medical University Hos-
aiwan.
Chen).
ciation. Published by Elsevier Taiw2. Epidemiology
InTaiwan, theprevalence rate of chlamydial infectionhasnot been
studied in the general population.4,5 Therefore, its rate (18.4%) was
estimated only on the basis of the number of patients visiting STI and
genitourinary clinics.6 Based on the classiﬁcation of STIs, the preva-
lence rates of chlamydial infection, gonorrhea, syphilis, human im-
munodeﬁciency virus infection, and trichomoniasis in genitourinary
clinics were 14.3%, 10.1%, 6.8%, 2.2%, and 0%, respectively.7 According
to the National Gonorrhea Notiﬁable Disease System (Taiwan), 55/
100,000people inTaiwanhavegonorrheal infection. Ina recent study,
however, Yu et al reported that the prevalence rate of untreated
asymptomatic chlamydial infectionwas high among young adults in
Taiwan. The study also concluded that approximately 40% of the in-
fections were either asymptomatic or subclinical.7 Therefore, chla-
mydial infection appears to have the highest incidence rate among
STIs recently. To prevent and treat STIs, any patientwho is visiting STI
clinics should be tested routinely for chlamydial infection.3. Risk factors
There are several risk factors that are responsible for chla-
mydial infection. Yu et al reported that independent risk factorsan LLC. Open access under CC BY-NC-ND license.
C.-S. Lien et al. / Urological Science 24 (2013) 7e98for chlamydial infection are younger age (30 years), inconsistent
condom use, being symptomatic (dysuria or urethral discharge) at
the time of testing, and having co-infection with N. gonorrhea.7 In
addition, people having more than three sexual partners, having
anonymous sexual partners, having new partners in the past 90
days, and having sex with someone met on the Internet have a
signiﬁcantly higher rate of chlamydial infection than those
without these risk factors.8 Drug users are at risk of chlamydial
infection because they tended to enjoy an unprotected sex, and
have greater numbers of anonymous sexual partners who had
STIs.4. Virulent serotypes
The most common genital chlamydial strain was genotype E,
followed by genotypes D and Da, F, K, J, G, and H.3 Although the
serotypes may be detected in patients, they may not show any
clinical symptoms; in fact, a previous study reported that
approximately 81% individuals with genotype E infection did not
present with any symptoms in comparison with only 26%
asymptomatic individuals with a non-E genotype infection.9 The
results of this study indicate that genotype E may less pathogenic.
However, the prevalence rate of chlamydial serotype may differ
between regions and countries. For example, serotype J has the
highest prevalence rate in the United States, while, in Taiwan, the
high prevalence rate of serotype E seems to be more similar to that
detected in Japan.95. Diagnosis of STI
Laboratory detection of C. trachomatis infection includes nucleic
acid ampliﬁcation test (NAAT), cell culture, direct immunoﬂuores-
cence, enzyme immunoassay (EIA), and nucleic acid hybridization
tests. The specimens are obtained from endocervical or vaginal
swabs (women) and urethral swab (men). Among these tests, NAAT
is themost sensitive and a Food and Drug Administration-approved
test for detecting the infection in urine samples.10,11 In one multi-
center trial, the sensitivities and speciﬁcities of NAAT performed on
self-obtained vaginal swabs ranged from 90.7 to 97.9% and 99.0 to
99.6%, respectively.12 This result is very close to the result from
endocervical swabs and can be easily done by patients themselves.
NAAT can be performed with different samples collected non-
invasively. NAAT has been validated for urine samples from both
men and women.13 Besides, NAAT has been proven to be sensitive
and speciﬁc in samples obtained from the rectum and pharynx
among homosexual men.14,15
Urethral discharge syndrome is diagnosed when a man com-
plains to have urethral discharge, which is considered to be related
to STIs. The sensitivity of urethral discharge syndrome differs
among various STIs. Syndromes such as discharge or genital ulcer
provide us an indication of the underlying infection to ensure its
suitable management.16 The detection rates of chlamydial, gono-
coccal, and a combination of the two forms of infection according to
syndromes were 31.8%, 58.5%, and 70.0%, respectively, with speci-
ﬁcities of 93.5%, 97.1%, and 93.9%, respectively.7 Positive predictive
values (PPVs) were 56.0%, 68.0%, and 28.0% for chlamydial infection,
gonococcal infection, and a combination of the two forms,
respectively. In contrast, the sensitivity of genital ulceration syn-
drome for syphilis detection was only 38.0%, although the speci-
ﬁcity was 82.5%, and the PPV was 32.0%. In addition to clinical
syndromes, risk assessment and rapid diagnostic tests offer an
effective method to reduce the number of false-positive results for
patients with STI. Therefore, patients with urethral discharge syn-
drome should be tested for chlamydial infection.6. Screening for chlamydial infection
Screening patients for chlamydial infection had been proven to
reduce the incidence of PID. Previous reports have suggested that
approximately 10% of womenwith chlamydial infectionwho did not
receive treatment for chlamydial infection developed symptomatic
PID.16,17 Therefore, annual screening of sexually active women, who
are under the age of 25 and with chlamydial infection is suggested.
The risk factors for chlamydial infection amongwomen include those
who have a new sexual partner or a recent history of chlamydial
infection.17 Nevertheless many women have antibodies which
consistent with a past chlamydial infectionmay result in tubal factor
infertility without prior history of clinical PID. This suggests that
chlamydial infection may cause subclinical PID resulting in infer-
tility.18e20 In women, screening may be accomplished by: (1) col-
lecting specimens from endocervical swabs or urine samples and
performing anNAAT, while pelvic examination is also acceptable; (2)
collecting specimens from endocervical swabs and performing an
unampliﬁed nucleic acid hybridization test, an EIA, or direct ﬂuo-
rescent antibody test; or (3) cell culturing using the collected endo-
cervical swab specimens. In men, the options for detecting the
infection are the same, except that intraurethral samples must be
used.NAATusingpolymerasechain reactionassay forurine isahighly
sensitive and noninvasive method for screening men and women
with chlamydial infection.When comparedwith culture and antigen
tests, NAAT revealed a double detection rate.1 Therefore, NAAT is a
reliable tool for screening patients with chlamydial infection.
However, these tests cannot replace pelvic examination or
endocervical culture in symptomatic women because the tests
cannot detect antibiotic sensitivity. Specimens for cell culture can
be obtained from urethral or cervical swabs, urine, or prostatic
ﬂuid. NAAT remains an alternative in patients when culture test
cannot be performed.1
The National Chlamydia Screening Programme (NCSP) is an NHS
sexual health program that was set up by the Department of Health
in England in 2003.21 The aims of NCSP are to ensure that all
sexually active young people under 25 years are aware of chla-
mydial infection and its effects as well as having access to free and
conﬁdential services providing testing, prevention, treatment, and
partner or contact management to reduce risks of infection or on-
ward transmission. The NCSP comprises a local screening program,
with each having a screening coordinator. The Health Protection
Agency (HPA), since November 2005, coordinates, facilitates, and
supports the establishment of the local Chlamydia screening pro-
grams. Almost 1.5 million Chlamydia tests have been performed by
the NCSP since its launch. Therefore, this program can be a good
reference model for setting up similar chlamydial screening centers
in Taiwan in the future.
7. Treatment
The ﬁrst-line treatment for chlamydial infection includes
administration of azithromycin (single dose of 1 g orally) or doxy-
cycline (100mg twice daily for 7 days). Both are primary treatments
and equally effective.10,22 Alternative therapies include adminis-
trationof an erythromycin-based regimen (500mg) four times daily,
erythromycin ethylsuccinate (800 mg) four times daily, oﬂoxacin
(300 mg) twice daily, or levoﬂoxacin (500 mg) daily for 7 days.10
In order to compare the efﬁcacy and safety between doxycycline
and azithromycin, a meta-analysis on 1543 patients with chla-
mydial infection was performed. The study results showed that the
cure rates were insigniﬁcant between both drugs (97% for azi-
thromycin and 98% for doxycycline, respectively).23 Therefore, it
was concluded that both drugs are equally effective for treating
chlamydial infection.
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Chlamydia-infected patients should be re-evaluated 3 months
after the initial treatment. There is a high prevalence of
C. trachomatis infection in patients whowere treated for chlamydial
infection during the preceding several months.10 Most post-
treatment re-infections are usually associated with the over-
looked sexual partner or new sexual acquaintances. Retesting 3e4
weeks after initial therapy is recommended only in pregnant
women, patients with poor drug compliance, instances or suspicion
of re-infection, or in cases where symptoms persistent. There is a
possibility of false-negative results if the number of chlamydial
organisms is limited; interestingly, the false-positive results might
also be due to the presence of nonviable organisms.10
9. Management of sexual partners
Any sexual partner should be referred for evaluation, testing,
and treatment if they had sexual contact with the patient during
the past 60 days at the onset of the patient’s symptoms or if
diagnosis of chlamydial infection is conﬁrmed. The last sexual
partner should be evaluated and treated, even if the time of last
sexual contact is over 60 days before the onset of symptom or
diagnosis.
In addition, abstinence from sexual intercourse has been sug-
gested until treatment completion in both the patient and his/her
sexual partner(s). Abstinence should be continued for at least 7
days (or more in some cases) after a single-dose regimen or after
completion of a multiple-dose regimen. The treatment for sexual
partners is very important for decreasing the risk of re-infection.10
10. Pregnancy
In pregnant women, untreated chlamydial infection can cause
premature delivery and low birth weight in the neonate. Eye and
respiratory tract chlamydial infection can occur in the neonate
during delivery, resulting in conjunctivitis and pneumonia,
respectively.24 In addition, untreated chlamydial infection may
affect future pregnancies as it is associated with higher risk of
infertility and ectopic pregnancy. Administration of doxycycline,
oﬂoxacin, and levoﬂoxacin are contraindicated in pregnant
women; in contrast, administration of azithromycin is safe and
effective according to clinical experience and published studies.
The patient should be retested to ensure complete eradication
(preferably by NAAT) of the infection 3 weeks after the therapy is
completed. This ensures cure and avoids severe complications that
might occur in mothers and neonates if the infection persists.10
11. Conclusion
Chlamydial infection is the most common STI caused by the
bacterium C. trachomatis and has a high prevalence rate of un-
treated asymptomatic individuals. Screening for chlamydial infec-
tion had been proven to reduce the incidence of pelvic
inﬂammatory disease, which has been considered to be related
with infertility. Therefore, young Taiwanese patients visiting STI
clinics should be routinely screened for chlamydial infection,
especially patients with high risk factors. Furthermore, the infected
patients should refer their sexual partners for evaluation, testing,
and treatment to avoid re-infection and help to prevent the spread
of chlamydial infection. In addition, these patients should be
retested 3 months later for chlamydial infection after complete
treatment. Retest should be done 3 weeks later after treatment to
ensure cure and avoid severe complications in pregnant women.Conﬂicts of interest statement
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